Clinical trials in Barcelona – page 47

3 147 clinical trials in Barcelona, Spain across 23 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Barcelona at a glance

3 147

clinical trials

Research sites23

Quick filters

3 147 trials in Barcelona

Open in trial search

Hypertriglyceridaemia

Recruiting

Study of Plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational

Study of Plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Lutetium (177Lu) Vipivotide Tetraxetan
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:IBUZATRELVIR
Sponsor:Pfizer Inc.

Contact Research Centre

Bullous impetigo+3

Recruiting

Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Registered drugNo placebo

Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Registered drugNo placebo

Spain

Participants:0–17 years
Sponsor:Laboratorios Ojer Pharma S.L.

Contact Research Centre

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:LY3372993
Sponsor:Washington University School Of Medicine

Contact Research Centre

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Prednisolone Acetate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery

InvestigationalNo placebo

Study of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azd0901
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barcelona

What the registry says about research in the country

01 Neurodegenerative Research

Innovative studies focusing on Alzheimer's Disease and Frontotemporal Dementia, utilizing advanced brain imaging techniques to track disease progression and evaluate new therapeutic approaches.

Cerebral tau aggregates assessment
Amyloid deposition tracking
Progressive supranuclear palsy research

Advanced neuroimaging studies using PET tracers to understand disease mechanisms.

02 Infectious Disease Prevention

Comprehensive vaccine trials targeting various infections including Respiratory Syncytial Virus, Cytomegalovirus, and Herpes Zoster.

RSV vaccine development for older adults
CMV prevention studies
COVID-19 booster research

Focus on developing effective immunization strategies for vulnerable populations.

03 Metabolic and Chronic Conditions

Research examining treatments for Type 1 Diabetes and obesity, alongside studies in bladder cancer and urinary tract infections.

Diabetes management therapies
Cancer immunotherapy trials
UTI vaccine development

Innovative approaches to chronic disease management and prevention.

Back to Spain All countries